The company has developed a proof-of-concept single-pore sensor that it anticipates integrating into a prototype testing platform this year.
An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.
Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.
The test adds to a menu of transplant monitoring assays that includes cytomegalovirus, Epstein-Barr virus, and BK virus.
The new test increases the multiplexing of the sepsis panel from 26 targets to 43 targets, including seven additional resistance genes.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.
The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.
The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.
The Church Lab spinout has now raised more than $50 million to develop and commercialize its fluorescent in situ sequencing technology for spatial genomics.
Quidel said that it expects fourth quarter 2019 revenues to be in the range of $151 million to $152 million, which would eclipse analyst expectations.
The firm also announced an exclusive distribution deal covering Israel for its T2 Resistance, T2Bacteria, and T2Candida panels
To market its analyte specific reagents, syndromic enteric panels, and other tests, the firm is building a US-based sales organization.
The clinical study will evaluate a next-generation sequencing-based test, which has the potential to detect all known respiratory pathogens in 12 hours.
The firm said its panel, which runs on its MDx-3000 system, tests nasopharyngeal swabs for the most common viruses and bacteria.
The startup is exploring options with potential partners and plans to bring a urinary tract infection test through regulatory channels in the next two years.
Clinical investigators have used Longhorn Vaccines and Diagnostics' qPCR approach in a study to detect M. tuberculosis DNA in the mouths of people at high risk for subclinical TB.
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
The new funding supports development of a rapid molecular test to detect bloodstream infections directly from whole blood.
The investment bank gave PerkinElmer an Outperform rating with a $114 stock price target and Hologic an In Line rating with a $55 stock price target.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
In Nature this week: epigenetic factors that prevent healthy aging and more.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.